---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-065339"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:24:14.730472+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaccinex enrolls 36 patients in KEYNOTE-B84 HNSCC study; interim analysis due mid-2023

## Summary
- Phase 1b/2 trial evaluating pepinemab + KEYTRUDA in recurrent/metastatic HNSCC.
- Enrollment of 36 subjects triggers pre-planned interim analysis; results expected mid-2023.
- Primary endpoints: safety (TEAEs) and objective response rate (ORR).
- Company notes improved durable responses in PD-L1 low (CPS<20) patient subset.
- Full study plans to enroll ~62 patients; pepinemab global rights held by Vaccinex.

## SEC filing metadata
- accession: 0001193125-23-065339
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312523065339/0001193125-23-065339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312523065339/d471144d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-065339
- JSON: https://secwatch.observer/filing/0001193125-23-065339.json
- Plain text: https://secwatch.observer/filing/0001193125-23-065339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.